NEW YORK, January 29, 2022 /PRNewswire/ —
WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of Reata Pharmaceuticals, Inc. RETA between November 9, 2020 and December 8, 2021, inclusive (the “Class Period”), of the substantial February 18, 2022 lead applicant deadline.
SO WHAT: If you purchased Reata Pharmaceuticals securities during the Class Period, you may be entitled to compensation without payment of out-of-pocket expenses or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Reata Pharmaceuticals class action lawsuit, go to http://www.rosenlegal.com/cases-register-2230.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court not later than February 18, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified lawyers with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Many of these companies do not bring securities class action lawsuits. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company obtained more than $438 million for investors. In 2020, founding partner Laurence Rosen has been named by law360 as a Titan of the Plaintiffs Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the Complaint, Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the FDA had raised concerns about the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) as a result, there was a significant risk that Reata’s New Drug Application would not be approved; and (3) as a result of the foregoing, defendants’ positive statements about Reata’s business, operations and prospects were materially misleading and/or lacked reasonable basis. When the real details entered the market, the lawsuit claims investors suffered damages.
To join the Reata Pharmaceuticals class action lawsuit, go to http://www.rosenlegal.com/cases-register-2230.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information.
No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future upturn does not depend on their status as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertisement. Previous results do not guarantee a similar result.
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-a-leading-law-firm-encourages-reata-pharmaceuticals-inc-investors-to-secure-counsel-before -important-18-February-time-limit-for-collective-recourse-titles–reta-301471076.html
SOURCE Rosen Law Firm, Pennsylvania